| 查看: 1673 | 回复: 1 | |||
[交流]
gliosis和glioma有什么区别？ 已有1人参与
|
|
查了些文献都没有谈清楚，有大神指点一下嘛 gliosis指胶质增生，glioma是胶质瘤，但是有时候又不太能分清楚。 |
回复此楼» 猜你喜欢
焦虑
已经有13人回复
-
一志愿985，本科211，0817化学工程与技术319求调剂
已经有8人回复
-
0817 化学工程 299分求调剂 有科研经历 有二区文章
已经有9人回复
-
346求调剂[0856]
已经有5人回复
-
285化工学硕求调剂（081700）
已经有11人回复
-
267一志愿南京工业大学0817化工求调剂
已经有9人回复
-
274求调剂
已经有6人回复
-
求材料调剂
已经有10人回复
-
本科郑州大学物理学院，一志愿华科070200学硕，346求调剂
已经有4人回复
-
国自科面上基金字体
已经有8人回复
zirow
木虫 (小有名气)
- 应助: 2 (幼儿园)
- 金币: 3751.8
- 红花: 3
- 帖子: 82
- 在线: 234.8小时
- 虫号: 1924189
- 注册: 2012-08-04
- 性别: MM
- 专业: 金融学
|
Gliosis versus glioma?: don't grade until you know. Marie Rivera-Zengotita Anthony T Yachnis Department of Pathology, Immunology, and Laboratory Medicine, University of Florida College of Medicine, Gainesville, USA. Advances in anatomic pathology (Impact Factor: 3.22). 07/2012; 19(4):239-49. DOI: 10.1097/PAP.0b013e31825c6a04 Source: PubMed ABSTRACT A major challenge in the routine practice of surgical neuropathology is the distinction between reactive astrocytosis, which may be because of non-neoplastic and neoplastic conditions, and a low-grade infiltrating diffuse astrocytoma [World Health Organization (WHO) grade II]. This can be particularly challenging with small biopsies that often yield limited amounts of tissue for pathologic study, especially considering the marked differences in prognosis and therapy after a pathologic diagnosis. This paper will review some basic principles of gliosis as an astrocytic reaction to a wide range of central nervous system insults and focus on some common diagnostic pitfalls such as (1) gliosis associated with brain tumor mimics, including demyelinating disease and infections, (2) gliosis associated with nonglial tumors such as craniopharyngioma, hemangioblastoma, metastases, and central nervous system lymphoma. New diagnostic methods have facilitated the differentiation between reactive astrocytosis and the diffuse gliomas. Of these, the use of mutated isocitrate dehydrogenase-1 (IDH-1) as a marker of diffuse infiltrating astroctomas, oligodendrogliomas, and a subset of glioblastomas (secondary glioblastomas) is particularly exciting for tissue diagnosis and patient prognosis. In addition IDH-1 may be useful to distinguish a diffuse infiltrating glioma from low-grade "focal" neoplasms such as the pilocytic astocytoma in histologically ambiguous cases. The discovery of BRAF mutations as molecular signatures of some pilocytic astrocytomas, gangliogliomas, and pleomorphic xanthoastrocytomas has provided another diagnostic tool for the pathologist. Only after a definitive diagnosis of a diffuse infiltrating glioma or a focal glioma is made should a tumor grade be applied and some practical issues in current glioma grading are provided. |
2楼2014-07-24 09:58:35
